MapLight Therapeutics MPLT Institutional Ownership

MapLight Therapeutics, Inc. (NASDAQ:MPLT) has 107 institutional investors with active 13F positions as of June 2026.

• These investors held 58.1% of outstanding shares in June 2026, down from 285.2% in March 2026.
• Their total shares held in MPLT increased 11.76% quarter over quarter, and separately, investors owning MapLight Therapeutics stayed flat from a year ago.
• During the quarter, 59 of these 107 funds increased positions in MPLT, 30 reduced exposure, and 18 held steady.
• The aggregate institutional position in MapLight Therapeutics amounted to 26.39Mn shares as of June 2026, up by 2.78Mn shares quarter on quarter, and with no net change year over year.
• Novo Holdings A/S leads ownership in MPLT with 3.69Mn shares as of June 30, 2026, equal to 8.11% of outstanding shares.
• The largest buyers of MapLight Therapeutics for the quarter ending June 2026 were PRICE T ROWE ASSOCIATES INC /MD/ (1.31Mn), Paradigm Biocapital Advisors LP (685.85K), FMR LLC (619.06K), State Street Corp (513.03K), Capital World Investors (415.73K).
• Leading sellers of MapLight Therapeutics shares for the quarter ending June 2026 were ADAR1 Capital Management, LLC (348.41K), BlackRock, Inc. (314.6K), Blue Owl Capital Holdings LP (276.0K), Freestone Grove Partners LP (145.05K), UBS Group AG (114.48K).
• MapLight Therapeutics's 10 largest shareholders as of June 2026 include Novo Holdings A/S (3.69Mn), FCPM III SERVICES B.V. (3.23Mn), T. Rowe Price Investment Management, Inc. (2.78Mn), Goldman Sachs Group Inc (1.95Mn), PRICE T ROWE ASSOCIATES INC /MD/ (1.42Mn), BlackRock, Inc. (1.03Mn), Nan Fung Group Holdings Ltd (971.25K), 5AM Venture Management, LLC (950.01K), Sanofi (912.04K), State Street Corp (852.15K) per Business Quant data.